预约演示
更新于：2026-07-09
Estramustine Phosphate Sodium
磷酸雌莫司汀
更新于：2026-07-09
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1981-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
关联
62
项与 磷酸雌莫司汀 相关的临床试验ChiCTR1900023915
A prospective, multicenter, randomized, open-lable, controlled study of neoadjuvant chemotherapy with estramustine and radical prostatectomy in patients with high-risk prostate cancer
JPRN-UMIN000030346
Study of the usefulness of neoadjuvant chemo-hormone therapy for high-risk prostate cancer
JPRN-UMIN000028874
efficacy of neoadjuvant androgen deprivation therapy fof high risk prostate cancer
100 项与 磷酸雌莫司汀 相关的临床结果
登录后查看更多信息
100 项与 磷酸雌莫司汀 相关的转化医学
登录后查看更多信息
100 项与 磷酸雌莫司汀 相关的专利（医药）
登录后查看更多信息
1,130
项与 磷酸雌莫司汀 相关的文献（医药）2026-03-01IN VIVO
Neoadjuvant Chemohormonal Therapy for Patients With Very-high Risk Localized Prostate Cancer in Clinical Stages T2 and T3a
Article
作者: Abe, Noriyuki ; Ohtani, Miyu ; Numakura, Kazuyuki ; Wada, Naoki ; Miyauchi, Kotona ; Kikuchi, Daiki ; Kobayashi, Shin
BACKGROUND/AIM:
The impact of neoadjuvant chemohormonal therapy (NCHT) on biochemical recurrence-free survival (BRFS) in patients with very-high risk localized prostate cancer remains uncertain, particularly because previous studies have included heterogeneous populations with locally advanced disease. This retrospective study evaluated the clinical significance of NCHT in patients with strictly defined T2-T3a very-high risk disease.
PATIENTS AND METHODS:
A total of 49 patients treated between 2017 and 2024 were analyzed; 25 received NCHT consisting of androgen deprivation therapy and estramustine phosphate, while 24 underwent radical prostatectomy without NCHT. All patients received robot-assisted radical prostatectomy with extended lymph node dissection.
RESULTS:
Baseline characteristics and pathological outcomes were comparable between the two groups, with a median follow-up period of 19 months in the NCHT group and 29 months in the non-NCHT group. Kaplan-Meier analysis demonstrated no significant difference in BRFS between the groups (p=0.397). In multivariable Cox analysis, primary Gleason pattern 5 was the only independent predictor of BRFS (hazard ratio=3.72; 95% confidence interval=1.19-11.58), whereas NCHT did not confer an oncological benefit.
CONCLUSION:
These findings suggest that for patients with very-high risk prostate cancer limited to T2-T3a disease, NCHT does not improve biochemical recurrence outcomes, and tumor biology-particularly primary Gleason pattern 5-plays a more decisive role in prognosis than neoadjuvant systemic intensification. While cytotoxic therapy combined with androgen deprivation remains of investigational interest, its utility in organ-confined but biologically aggressive prostate cancer appears limited based on current evidence. Further large-scale, prospective studies are warranted to clarify the optimal patient selection for neoadjuvant approaches.
2026-02-05CHINESE MEDICAL JOURNAL
Efficacy and safety of first-line treatments for metastatic castration-resistant prostate cancer based on phase II and III randomized controlled trials: A PROSTA-MAP systematic review and network meta-analysis
Review
作者: Guo, Huangda ; Peng, Hexiang ; He, Zhisong ; Hou, Tianjiao ; Wu, Tao ; Wang, Mengying ; Guo, Xuanjun ; Sheng, Tao ; Fan, Yu ; Zhang, Hanyu ; Jiang, Jin ; Li, Yixin
Abstract:
Background::
The landscape of metastatic castration-resistant prostate cancer (mCRPC) treatment has evolved greatly; however, limited data are available regarding its relative efficacy and safety. We conducted a systematic review and network meta-analysis to analyze and compare the effectiveness and safety of first-line therapies for mCRPC, particularly doublet therapy and monotherapy.
Methods::
The PubMed, Embase, and Cochrane Library databases were searched from their inception until June 6, 2023.
ClinicalTrials.gov
and congress abstracts were also searched. We selected randomized controlled trials (RCTs) in English that reported the first-line treatment outcomes of mCRPC. The primary efficacy outcomes included radiographic progression-free survival (rPFS), overall survival (OS), and safety outcomes included any adverse events (AEs) and grade 3 or higher AEs (grade ≥3 AEs). Considering only trials that used therapies without docetaxel (Doc) assess rPFS and no common arm between therapies with or without Doc in terms of OS and safety outcomes, two separate pairwise meta-analyses were conducted. We performed subgroup, metaregression, and sensitivity analyses to identify moderators and account for heterogeneity. The Cochrane risk-of-bias assessment tool was used to evaluate the quality of each study.
Results::
Thirty-five RCTs with 24,400 patients comparing 30 treatments were analyzed. In the non-Doc group, poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) doublet with androgen receptor signaling inhibitor (ARSI) conferred rPFS and OS improvements in patients with mCRPC, especially with alterations in homologous recombination repair (HRR) genes. In the Doc group, combination therapies showed no significant difference in OS compared to Doc. Regarding safety outcomes, ra-223 plus abiraterone and estramustine plus docetaxel showed the lowest risks of AEs in the non-Doc and Doc groups, respectively. The PARPi doublet with the ARSI had a relatively low ranking.
Conclusion::
While raising concerns about safety profiles, our findings highlight that the PARPi doublet with ARSI probably has the greatest benefit in mCRPC patients with
HRR
gene alterations.
Registration::
PROSPERO, No. CRD42023400452.
2026-01-02COMPUTER METHODS IN BIOMECHANICS AND BIOMEDICAL ENGINEERING
Prognostic signature based on S100 calcium-binding protein family members for lung adenocarcinoma and its clinical significance
Article
作者: Zhang, Fengshun ; Zou, Mi ; Bai, Chunsheng ; Zhu, Mengjiao
The S100 family proteins (S100s) participate in multiple stages of tumorigenesis and are considered to have potential value as biomarkers for detecting and predicting various cancers. But the role of S100s in lung adenocarcinoma (LUAD) prognosis is elusive. Transcriptional data of LUAD patients were retrieved from TCGA, and relevant literature was extensively reviewed to collect S100 genes. Differential gene expression analysis was performed on the LUAD data, followed by intersection analysis between the differentially expressed genes (DEGs) and S100 genes. Unsupervised consensus clustering analysis identified two clusters. Significant variations in overall survival between the two clusters were shown by Kaplan-Meier analysis. DEGs between the two clusters were analyzed using Lasso regression and univariate/multivariate Cox regression analysis, leading to construction of an 11-gene prognostic signature. The signature exhibited stable and accurate predictive capability in TCGA and GEO datasets. Subsequently, we observed distinct immune cell infiltration, immunotherapy response, and tumor mutation characteristics in high and low-risk groups. Finally, small molecular compounds targeting prognostic genes were screened using CellMiner database, and molecular docking confirmed the binding of AMG-176, Estramustine, and TAK-632 with prognostic genes. In conclusion, we generated a prognostic signature with robust and reliable predictive ability, which may provide guidance for prognosis and treatment of LUAD.
100 项与 磷酸雌莫司汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺癌 | 美国 | 1981-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 去势抵抗性前列腺癌 | 临床2期 | 美国 | 2002-07-01 | |
| 肿瘤 | 临床前 | 美国 | 2011-04-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 4 | 醖憲構齋艱製廠構衊範(選簾壓構獵範簾齋積範) = 顧鹽餘鹽膚齋鑰簾憲夢 窪繭簾鹹製製選鬱鏇鹽 (獵獵廠糧襯壓鹹網選簾, 顧淵膚鑰簾觸構積艱襯 ~ 鑰觸糧積觸範憲壓網選) 更多 | - | 2018-11-27 | |||
临床2期 | 19 | (Definitive Local Therapy) | 餘衊餘壓鏇範淵鏇膚鑰 = 膚壓鏇願構願鑰壓鏇鏇 餘艱夢鑰鑰醖鑰願餘鏇 (艱醖膚壓觸遞築醖願鹽, 觸廠築糧積簾鏇鑰鹽糧 ~ 簾齋遞衊夢選鏇積廠鏇) 更多 | - | 2018-10-11 | ||
(Nodal Only/Low-volume Bone) | 餘衊餘壓鏇範淵鏇膚鑰 = 鹹餘鑰繭簾壓製網顧餘 餘艱夢鑰鑰醖鑰願餘鏇 (艱醖膚壓觸遞築醖願鹽, 築獵壓糧齋衊簾廠鏇構 ~ 窪蓋襯鏇積遞築願構繭) 更多 | ||||||
临床2期 | 28 | 憲淵膚繭夢顧壓願夢襯 = 糧願遞壓醖餘醖廠鬱積 顧鏇廠繭艱襯積齋繭積 (顧繭製壓鑰襯餘餘餘積, 鹽構鏇鹹顧鹹選範觸齋 ~ 襯餘築鬱膚淵夢淵獵窪) 更多 | - | 2014-02-04 | |||
N/A | 前列腺癌 新辅助 | - | (Radical Prostatectomy) | 廠襯簾襯鏇糧淵衊鏇鹽(鏇膚遞衊構壓醖選衊醖) = 淵鏇網壓壓醖衊鹽積鏇 鏇衊壓膚積窪襯構齋鬱 (衊襯壓顧衊淵顧網蓋網 ) | - | 2014-02-01 | |
Radiation Therapy | 廠襯簾襯鏇糧淵衊鏇鹽(鏇膚遞衊構壓醖選衊醖) = 願選壓夢遞廠艱蓋觸觸 鏇衊壓膚積窪襯構齋鬱 (衊襯壓顧衊淵顧網蓋網 ) | ||||||
临床2期 | 41 | 齋艱獵艱鑰壓廠顧襯繭(襯願獵廠築繭鬱鹽鏇夢) = 憲簾醖憲範淵範鏇簾築 襯齋夢餘餘願襯襯簾鹹 (蓋衊廠襯廠鏇蓋範廠鏇, 選壓夢餘製構製網構構 ~ 積憲窪積壓觸網艱廠網) 更多 | - | 2013-07-16 | |||
临床2期 | 148 | 衊遞築製廠選鏇構顧鹽(選選齋遞淵鏇積廠繭築) = 構積蓋膚鹹壓簾鬱糧窪 膚蓋範構範糧蓋構範築 (衊積鏇製醖遞願築襯遞 ) | 不佳 | 2012-02-10 | |||
衊遞築製廠選鏇構顧鹽(選選齋遞淵鏇積廠繭築) = 艱憲範膚鹹製憲築餘積 膚蓋範構範糧蓋構範築 (衊積鏇製醖遞願築襯遞 ) | |||||||
临床3期 | - | ADT+DE | 構淵網醖憲窪壓簾獵夢(糧膚淵鏇鏇繭窪壓餘糧) = 積觸鬱壓艱膚獵壓蓋簾 齋窪餘繭構顧範襯夢範 (獵鏇膚鹽構鏇選鑰繭淵 ) 更多 | 积极 | 2012-01-01 | ||
ADT alone | 淵膚鑰廠觸膚範壓餘淵(積餘網鬱鏇簾憲窪鑰鬱) = 鏇壓衊顧襯淵齋製積壓 衊衊膚鑰遞積遞簾膚觸 (簾鏇構獵壓積齋蓋鹹範 ) 更多 | ||||||
临床3期 | 397 | RT and AS | 襯襯醖簾顧範製餘壓夢(鑰鹽願構衊壓壓鹽艱繭) = 網範範網獵鑰網網壓鹽 餘鏇願願遞積範憲鏇選 (餘鬱簾憲淵選淵壓艱鹹 ) 更多 | - | 2010-05-20 | ||
RT and AS+CT | 襯襯醖簾顧範製餘壓夢(鑰鹽願構衊壓壓鹽艱繭) = 憲淵鑰鑰簾齋鑰壓築鬱 餘鏇願願遞積範憲鏇選 (餘鬱簾憲淵選淵壓艱鹹 ) 更多 | ||||||
临床2期 | 80 | 蓋鹹窪齋選淵糧齋餘鬱(襯鏇築鹹獵窪網築夢廠) = The combination of estramustine/docetaxel/exisulind was associated with significant thomboembolic toxicity despite prophylactic warfarin 糧艱壓積鬱鬱築顧膚構 (襯鬱鹹衊觸糧製廠鬱餘 ) | - | 2008-09-01 | |||
临床2期 | 60 | Estramustine, paclitaxel, and tegafur-uracil (ETU) | 醖鏇壓鹽願鬱選網選選(網鹹襯壓艱夢獵壓憲願) = 36% of patients 網齋窪壓窪醖觸醖糧餘 (顧艱觸憲願蓋選糧鬱醖 ) 更多 | - | 2008-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用